Low-grade Serous Ovarian Carcinoma

In the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciardi, Enzo, Baert, Thaïs, Ataseven, Beyhan, Heitz, Florian, Prader, Sonia, Bommert, Mareike, Schneider, Stephanie, du Bois, Andreas, Harter, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195427/
https://www.ncbi.nlm.nih.gov/pubmed/30364401
http://dx.doi.org/10.1055/a-0717-5411
Descripción
Sumario:In the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.

Ejemplares similares